Molecular Oncology and Embryology Laboratory, Department of Surgery and Medical Specializations, Human Anatomy Unit, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), c. Casanova 143, 08036 Barcelona, Spain.
Department of Thoracic Surgery, Hospital Clínic de Barcelona, University of Barcelona, 08036 Barcelona, Spain.
Int J Mol Sci. 2022 Jun 27;23(13):7138. doi: 10.3390/ijms23137138.
In resected non-small cell lung cancer (NSCLC), post-surgical recurrence occurs in around 40% of patients, highlighting the necessity to identify relapse biomarkers. An analysis of the extracellular vesicle (EV) cargo from a pulmonary tumor-draining vein (TDV) can grant biomarker identification. We studied the pulmonary TDV EV-miRNAome to identify relapse biomarkers in a two-phase study (screening and validation). In the screening phase, a 17-miRNA relapse signature was identified in 18 selected patients by small RNAseq. The most expressed miRNA from the signature (EV-miR-203a-3p) was chosen for further validation. Pulmonary TDV EV-miR-203a-3p was studied by qRT-PCR in a validation cohort of 70 patients, where it was found to be upregulated in relapsed patients ( = 0.0194) and in patients with cancer spread to nearby lymph nodes (N+ patients) ( = 0.0396). The ROC curve analysis showed that TDV EV-miR-203a-3p was able to predict relapses with a sensitivity of 88% (AUC: 0.67; = 0.022). Moreover, patients with high TDV EV-miR-203a-3p had a shorter time to relapse than patients with low levels (43.6 vs. 97.6 months; = 0.00703). The multivariate analysis showed that EV-miR-203a-3p was an independent, predictive and prognostic post-surgical relapse biomarker. In conclusion, pulmonary TDV EV-miR-203a-3p is a promising new relapse biomarker for resected NSCLC patients.
在切除的非小细胞肺癌 (NSCLC) 中,约 40%的患者术后会复发,这突出表明需要确定复发的生物标志物。分析来自肺肿瘤引流静脉 (TDV) 的细胞外囊泡 (EV) 货物可以鉴定生物标志物。我们通过小 RNAseq 对 18 名选定患者的肺 TDV EV-miRNAome 进行了分析,以鉴定复发生物标志物。在筛选阶段,从签名中选择了最表达的 miRNA (EV-miR-203a-3p) 进行进一步验证。通过 qRT-PCR 在 70 名患者的验证队列中研究了肺 TDV EV-miR-203a-3p,发现其在复发患者中上调 ( = 0.0194) ,并且在癌症扩散到附近淋巴结的患者中上调 (N+患者) ( = 0.0396)。ROC 曲线分析表明,TDV EV-miR-203a-3p 能够以 88%的灵敏度预测复发 (AUC:0.67; = 0.022)。此外,具有高 TDV EV-miR-203a-3p 的患者比具有低水平的患者复发时间更短 (43.6 与 97.6 个月; = 0.00703)。多变量分析表明,EV-miR-203a-3p 是术后复发的独立、预测和预后生物标志物。总之,肺 TDV EV-miR-203a-3p 是一种有前途的新的 NSCLC 切除患者复发生物标志物。